SciBase - Interim report
January 1 - March 31, 2021
The first quarter in figures
Net sales amounted to TSEK 2,562 (2,469).
The loss after tax amounted to TSEK 8,153 (8,936).
The loss per share amounted to SEK 0.15 (0.54).
The cash flow from current operations was negative in the amount of TSEK 9,473 (7,893).
The gross margin reached 52.7% (54.0%).
Electrode sales volume increased by 14% and reached 7,496 (6,562) units, a new quarterly high. Repeat sales of electrodes to existing customers increased by 18%.
Important events during the quarter
Covid-19 continues to affect sales and the market situation remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities. Sales in the company s key market Germany increased by 3%(cleared for currency effects +9%) while overall sales increased by 3% (cleared for currency effects +9%).
Share this article
STOCKHOLM, May 11, 2021 /PRNewswire/
SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the launch of the new Non-Melanoma Skin Cancer (NMSC) clinical application following the completion of their MDR certification process.
SciBase s strategy is to leverage the Nevisense technology platform to launch additional clinical applications and products. The first clinical application or indication to be added is NMSC, initially for Nevisense 3.0.
There are two types of skin cancer: melanoma and non-melanoma skin cancer (NMSC). NMSC is more than ten times more prevalent than melanoma and comes itself in primarily two forms: basal cell carcinoma and squamous cell carcinoma. Although NMSC is less harmful and deadly than melanoma, it is still important that it is detected early and is managed with the most appropriate therapy. Because Dermatologists see many more patients with s
SciBase receives important European MDR certification
STOCKHOLM, May 10, 2021 /PRNewswire/
SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that it has been granted certification under the new Medical Device Regulation (MDR).
MDR is a set of mandatory legal requirements central for all companies selling medical devices in the EU. The new regulation comes into effect on May 26
th. SciBase is one of very few medical device manufacturers to have completed the MDR certification, after an intensive two year process. With the MDR Certification in place SciBase can release new products, indications and functionality such as their new Non-melanoma Skin cancer (NMSC) application.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Non-Melanoma Skin Cancer Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com
May 7, 2021 GMT
DUBLIN (BUSINESS WIRE) May 7, 2021
Global Non-Melanoma Skin Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Melanoma Skin Cancer epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.
The research provides population data to characterize Non-Melanoma Skin Cancer patients, history of the disease at the population level (Non-Melanoma Skin Cancer prevalence, Non-Melanoma Skin Cancer incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.
Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer
Company Expects to Report Initial Clinical Data in Second Half of 2021
News provided by
Share this article
Share this article
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 25, 2021 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of the Phase 2b study of the company s lead drug candidate, STP705, for the treatment of squamous cell skin cancer.
The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of intralesional injection of STP705 in 100 adult patients with squamous cell carcinoma